Kelly Boothe Email

VP Investor Relations & Corporate Communications . Aeglea BioTherapeutics

Current Roles

Employees:
36
Revenue:
$3.9M
About
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Aeglea BioTherapeutics Address
221 Crescent Street
Austin, TX
United States
Aeglea BioTherapeutics Email

Past Companies

Carmot Therapeutics, Inc.Vice President, Investor Relations and Corporate Communications
Self-employedIR & Corporate Communications Consultant
Aeglea BioTherapeuticsVice President of Investor Relations & Corporate Communications

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.